Senate's User Fee Bill Largely Steers Clear Of Controversy
HELP Committee manager’s amendment lacks provisions on such hot-button issues as off-label drug promotion, REMS abuses and right-to-try legislation.
You may also be interested in...
US Congressional staff pitch bills for rare disease patients and advocates to talk up while on Capitol Hill, but one that likely would delay generic entry may be a tough sell.
Web tool to help patients find expanded access program should go live in early June, focusing initially on oncology. That timing should help deflect efforts to enact “Right to Try” legislation.
Senate committee forced to postpone mark-up of FDA user fee reauthorization legislation; drug pricing fight may be postponed by hearing pledge.